Perspectives in the Application of Immunocorrector – transfer factor ™ in Immunoprophylaxis Programmes and Immunorehabilitation

Abstract

Background. Human health is largely determined by the body’s resistance to various damaging factors and, in particular, the functional state of its immune system. The use of unique, new generation immunomodulators in prevention of diseases is promising. Goal of the research was to defne the perspectives in the application of immunocorrector Transfer factorTM in immunoprophylaxis programmes and immunorehabilitation analysing and summarizing scientifc articles. Methods. Systemic literature overview was performed, including 77 scientifc articles and conference proceedings in English, published in the period from 1949 to 2016. The main inclusion criterion was clinical trial or literature review, analysing the effect of immunocorrector on human health in cases of different disorders.  Results. Transfer factors are molecules that communicate antigenic immunological information intracellularly from a donor to a recipient. Mammalian Transfer factors, including those of humans are small molecules between 3,500 and 10,000 Daltons. Transfer factor’s functions of cell-mediated immunity and non-specifc immunological activity differ from the functions of antibodies. Transfer factors are divided into three fractions: the inductors that provide rapid immune response and general readiness of the immune system; suppressors, which regulate the intensity of the immune response, preventing allergic and autoimmune reactions; antigen specifc Transfer factors with a set of certain antigens, allowing quick adjusting of the immune system to recognize many bacterial and viruses. Conclusions. Transfer factors have no side effects and are considered as highly effective in treatment of infectious, parasitic, oncological, dermatological, venereal and somatic diseases, so are highly recommended for preventive purposes and decreasing of aging.]

Keywords: transfer factor, immunoprophylaxis, immunorehabilitation.